Garnet L Anderson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/42020/publications.pdf

Version: 2024-02-01

166 papers	39,742 citations	18465 62 h-index	5820 161 g-index
174 all docs	174 docs citations	174 times ranked	28159 citing authors

#	Article	IF	Citations
1	The Association of Predicted Resting Energy Expenditure with Risk of Breast Cancer among Postmenopausal Women in the Women's Health Initiative Cohort. Cancer Prevention Research, 2022, 15, 255-264.	0.7	2
2	Mortality Associated with Healthy Eating Index Components and an Empirical-scores Healthy Eating Index in a Cohort of Postmenopausal Women. Journal of Nutrition, 2022, , .	1.3	1
3	The Impact of the COVID-19 Pandemic on Older Women in the Womenâ€™s Health Initiative. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, S3-S12.	1.7	11
4	Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. American Journal of Clinical Nutrition, 2022, 115, 1501-1510.	2.2	17
5	Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. American Journal of Clinical Nutrition, 2022, 115, 1490-1500.	2.2	71
6	Design and baseline characteristics of participants in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS). Contemporary Clinical Trials, 2022, 116, 106728.	0.8	10
7	Analgesic Use and Circulating Estrogens, Androgens, and Their Metabolites in the Women's Health Initiative Observational Study. Cancer Prevention Research, 2022, 15, 173-183.	0.7	0
8	Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer.. Journal of Clinical Oncology, 2022, 40, 10509-10509.	0.8	1
9	Contributions of the Womenâ€™s Health Initiative to Cardiovascular Research. Journal of the American College of Cardiology, 2022, 80, 256-275.	1.2	5
10	Determinants, circumstances and consequences of injurious falls among older women living in the community. Injury Prevention, 2021, 27, 34-41.	1.2	8
11	Reply to The Women's Health Initiative; hormone replacement therapy; and Surveillance, Epidemiology, and End Results data and The importance of comprehensive data and statistical testing in the interpretation of breast cancer incidence trends. Cancer, 2021, 127, 813-814.	2.0	1
12	Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50â€“59 Years of Age. American Journal of Epidemiology, 2021, 190, 365-375.	1.6	27
13	Nutritional epidemiology and the Womenâ€™s Health Initiative: a review. American Journal of Clinical Nutrition, 2021, 113, 1083-1092.	2.2	14
14	The association between heart failure and incident cancer in women: an analysis of the Women's Health Initiative. European Journal of Heart Failure, 2021, 23, 1712-1721.	2.9	19
15	Obesity, Height, and Serum Androgen Metabolism among Postmenopausal Women in the Women's Health Initiative Observational Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2018-2029.	1.1	8
16	Recreational physical activity, sitting, and androgen metabolism among postmenopausal women in the Women's Health Initiative Observational Study. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0809.2021.	1.1	0
17	Guidelineâ€concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study. International Journal of Cancer, 2020, 147, 404-412.	2.3	9
18	Association of Powder Use in the Genital Area With Risk of Ovarian Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 49.	3.8	41

#	Article	IF	Citations
19	Mediation by differential DNA methylation of known associations between single nucleotide polymorphisms and bladder cancer risk. BMC Medical Genetics, 2020, 21, 228.	2.1	4
20	Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Womenâ€™s Health Initiative Randomized Clinical Trials. JAMA - Journal of the American Medical Association, 2020, 324, 369.	3.8	210
21	Association of Prediagnostic Frailty, Change in Frailty Status, and Mortality After Cancer Diagnosis in the Womenâ€™s Health Initiative. JAMA Network Open, 2020, 3, e2016747.	2.8	25
22	Lights on MsFLASH: a review of contributions. Menopause, 2020, 27, 473-484.	0.8	16
23	Can dietary self-reports usefully complement blood concentrations for estimation of micronutrient intake and chronic disease associations?. American Journal of Clinical Nutrition, 2020, 112, 168-179.	2.2	8
24	Fortyâ€year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women. Cancer, 2020, 126, 2956-2964.	2.0	17
25	Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Womenâ€™s Health Initiative Randomized Trial. Journal of Clinical Oncology, 2020, 38, 1419-1428.	0.8	87
26	Prediagnosis social support, social integration, living status, and colorectal cancer mortality in postmenopausal women from the women's health initiative. Cancer, 2020, 126, 1766-1775.	2.0	15
27	The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Womenâ€™s Health Initiative. Breast Cancer Research and Treatment, 2020, 180, 747-757.	1.1	16
28	Dual-Outcome Intention-to-Treat Analyses in the Womenâ€™s Health Initiative Randomized Controlled Hormone Therapy Trials. American Journal of Epidemiology, 2020, 189, 972-981.	1.6	7
29	Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. Journal of the National Cancer Institute, 2019, 111, 137-145.	3.0	43
30	Postmenopausal Androgen Metabolism and Endometrial Cancer Risk in the Womenâ€™s Health Initiative Observational Study. JNCI Cancer Spectrum, 2019, 3, pkz029.	1.4	30
31	Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Womenâ€™s Health Initiative Observational Study. Cancer Causes and Control, 2019, 30, 1201-1211.	0.8	13
32	Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study. International Journal of Cancer, 2019, 145, 2051-2060.	2.3	15
33	Low-Fat Dietary Pattern among Postmenopausal Women Influences Long-Term Cancer, Cardiovascular Disease, and Diabetes Outcomes. Journal of Nutrition, 2019, 149, 1565-1574.	1.3	39
34	Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prevention Research, 2019, 12, 481-490.	0.7	14
35	Application of blood concentration biomarkers in nutritional epidemiology: example of carotenoid and tocopherol intake in relation to chronic disease risk. American Journal of Clinical Nutrition, 2019, 109, 1189-1196.	2.2	27
36	An Environmental Scan of Biopsychosocial and Clinical Variables in Cohort Studies of Cancer Survivors. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1621-1641.	1.1	3

#	Article	IF	Citations
37	Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?. International Journal of Cancer, 2019, 144, 730-740.	2.3	8
38	The influence of obesity-related factors in the etiology of renal cell carcinomaâ€"A mendelian randomization study. PLoS Medicine, 2019, 16, e1002724.	3.9	59
39	Weight loss and breast cancer incidence in postmenopausal women. Cancer, 2019, 125, 205-212.	2.0	66
40	The Women's Health Initiative (WHI) Life and Longevity After Cancer (LILAC) Study: Description and Baseline Characteristics of Participants. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 125-137.	1.1	42
41	The Yet Unrealized Promise of Ovarian Cancer Screening. JAMA Oncology, 2018, 4, 456.	3.4	10
42	Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials. Sleep, 2018, 41, .	0.6	67
43	Low-Fat Dietary Pattern and Cancer Mortality in the Womenâ€™s Health Initiative (WHI) Randomized Controlled Trial. JNCI Cancer Spectrum, 2018, 2, pky065.	1.4	14
44	Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival. JAMA Oncology, 2018, 4, e181212.	3.4	62
45	Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. Cancer Epidemiology, 2018, 56, 83-89.	0.8	4
46	Low-fat dietary pattern and cardiovascular disease: results from the Womenâ€™s Health Initiative randomized controlled trial. American Journal of Clinical Nutrition, 2017, 106, 35-43.	2.2	67
47	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nature Communications, 2017, 8, 15724.	5.8	106
48	Sitting, physical activity, and serum oestrogen metabolism in postmenopausal women: the Womenâ€™s Health Initiative Observational Study. British Journal of Cancer, 2017, 117, 1070-1078.	2.9	14
49	Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality. JAMA - Journal of the American Medical Association, 2017, 318, 927.	3.8	407
50	Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Womenâ€™s Health Initiative Observational Study. Breast Cancer Research, 2017, 19, 28.	2.2	21
51	Effects of Yoga and Aerobic Exercise on Actigraphic Sleep Parameters in Menopausal Women with Hot Flashes. Journal of Clinical Sleep Medicine, 2017, 13, 11-18.	1.4	35
52	Low-Fat Dietary Pattern and Breast Cancer Mortality in the Womenâ€™s Health Initiative Randomized Controlled Trial. Journal of Clinical Oncology, 2017, 35, 2919-2926.	0.8	104
53	Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1059-1063.	1.1	25
54	Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1081-1089.	1.1	76

#	Article	IF	Citations
55	Use of administrative data to increase the practicality of clinical trials: Insights from the Womenâ€™s Health Initiative. Clinical Trials, 2016, 13, 519-526.	0.7	19
56	Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 648-656.	1.1	47
57	Narrowing of racial disparities in breast cancer incidence: insights from menopausal hormone therapy study findings. Journal of the National Cancer Institute, 2016, 108, djv393.	3.0	1
58	Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 917-924.	2.3	16
59	Obesity and inflammation markers in relation to leukocyte telomere length in a cross-sectional study of persons with Barrettâ€™s esophagus. BMC Obesity, 2015, 2, 32.	3.1	18
60	Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. Obstetrics and Gynecology, 2015, 126, 413-422.	1.2	47
61	Optimal Cutoffs of Obesity Measures in Relation to Cancer Risk in Postmenopausal Women in the Women's Health Initiative Study. Journal of Women's Health, 2015, 24, 218-227.	1.5	16
62	Association Between Obesity and Postmenopausal Breast Cancer Riskâ€"Reply. JAMA Oncology, 2015, 1, 1171.	3.4	0
63	Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer. Journal of Clinical Oncology, 2015, 33, 1186-1190.	0.8	17
64	Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection. Journal of the National Cancer Institute, 2015, 107, .	3.0	20
65	Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk. JAMA Oncology, 2015, 1, 611.	3.4	451
66	Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index: Figure 1.. Journal of the National Cancer Institute, 2015, 108, djv327.	3.0	29
67	A Prospective Evaluation of Endogenous Sex Hormone Levels and Colorectal Cancer Risk in Postmenopausal Women. Journal of the National Cancer Institute, 2015, 107, djv210.	3.0	92
68	Menopausal hormone therapy and breast cancer mortality: clinical implications. Therapeutic Advances in Drug Safety, 2015, 6, 45-56.	1.0	26
69	Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. Gynecologic Oncology, 2015, 139, 253-260.	0.6	17
70	Efficacy of exercise for menopausal symptoms. Menopause, 2014, 21, 330-338.	0.8	134
71	Methods for the design of vasomotor symptom trials. Menopause, 2014, 21, 45-58.	0.8	57
72	Inflammation and Oxidative Stress Markers and Esophageal Adenocarcinoma Incidence in a Barrett's Esophagus Cohort. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2393-2403.	1.1	35

#	Article	IF	Citations
73	Low-Dose Estradiol and the Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor Symptoms. JAMA Internal Medicine, 2014, 174, 1058.	2.6	160
74	Efficacy of omega-3 for vasomotor symptoms treatment. Menopause, 2014, 21, 347-354.	0.8	64
75	Efficacy of yoga for vasomotor symptoms. Menopause, 2014, 21, 339-346.	0.8	94
76	Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. American Journal of Obstetrics and Gynecology, 2014, 210, 244.e1-244.e11.	0.7	66
77	Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage. Cancer Causes and Control, 2014, 25, 969-976.	0.8	31
78	Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Research, 2014, 16, R30.	2.2	22
79	Menopausal hormone therapy and cancer: Changing clinical observations of target site specificity. Steroids, 2014, 90, 53-59.	0.8	32
80	Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial. Annals of Internal Medicine, 2014, 160, 594.	2.0	53
81	Incidental genetic findings in randomized clinical trials: recommendations from the Genomics and Randomized Trials Network (GARNET). Genome Medicine, 2013, 5, 7.	3.6	13
82	A Statistical Perspective on Prevention Trials: A View from the Womenâ€™s Health Initiative. Statistics in Biosciences, 2013, 5, 330-343.	0.6	1
83	Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes and Control, 2013, 24, 209-215.	0.8	102
84	Risk of Recurrent Helicobacter pylori Infection 1 Year After Initial Eradication Therapy in 7 Latin American Communities. JAMA - Journal of the American Medical Association, 2013, 309, 578.	3.8	72
85	Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Womenâ€™s Health Initiative Observational Study. Journal of the National Cancer Institute, 2013, 105, 526-535.	3.0	165
86	Womenâ€™s Health Initiative View of Estrogen Avoidance and All-Cause Mortality. American Journal of Public Health, 2013, 103, e2-e2.	1.5	1
87	Lessons Learned From the WomenÊ¼s Health Initiative Trials of Menopausal Hormone Therapy. Obstetrics and Gynecology, 2013, 121, 172-176.	1.2	89
88	Changing Concepts: Menopausal Hormone Therapy and Breast Cancer. Journal of the National Cancer Institute, 2012, 104, 517-527.	3.0	125
89	Treatment of Helicobacter pylori in Latin America â€“ Authors' reply. Lancet, The, 2012, 379, 408-409.	6.3	3
90	Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncology, The, 2012, 13, 476-486.	5.1	314

#	Article	IF	Citations
91	Obesity and the Risk for Premenopausal and Postmenopausal Breast Cancer. Cancer Prevention Research, 2012, 5, 515-521.	0.7	76
92	Migraine History, Nonsteroidal Anti-inflammatory Drug Use, and Risk of Postmenopausal Endometrial Cancer. Hormones and Cancer, 2012, 3, 240-248.	4.9	7
93	Su1673 H. pylori Recurrence One Year After Eradication Treatment in a Population Randomized Trial (SWOG S0701) in Seven Latin American Sites. Gastroenterology, 2012, 142, S-478-S-479.	0.6	2
94	1046 Predictors of Success of Helicobacter pylori Eradication Treatment in a Multicentric Randomized Clinical Trial (SWOG S0701) in Latin America. Gastroenterology, 2012, 142, S-183-S-184.	0.6	2
95	Su1677 Risk Factors for Helicobacter pylori Infection in Six Latin American Countries (SWOG Trial) Tj ETQq1 1 0.784314 rgBT /Overlock	0.6	1
96	Use of alternative time scales in Cox proportional hazard models: implications for timeâ€varying environmental exposures. Statistics in Medicine, 2012, 31, 3320-3327.	0.8	53
97	Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. Breast Cancer Research and Treatment, 2012, 131, 969-979.	1.1	23
98	Abstract 1031: Estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy. , 2012, , .		0
99	Hormonal Factors and Risks of Esophageal Squamous Cell Carcinoma and Adenocarcinoma in Postmenopausal Women. Cancer Prevention Research, 2011, 4, 840-850.	0.7	50
100	14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet, The, 2011, 378, 507-514.	6.3	239
101	Projecting Individualized Absolute Invasive Breast Cancer Risk in Asian and Pacific Islander American Women. Journal of the National Cancer Institute, 2011, 103, 951-961.	3.0	148
102	Potential Role of HE4 in Multimodal Screening for Epithelial Ovarian Cancer. Journal of the National Cancer Institute, 2011, 103, 1630-1634.	3.0	47
103	Breast Cancer in Postmenopausal Women After Hormone Therapyâ€"Reply. JAMA - Journal of the American Medical Association, 2011, 305, 466.	3.8	0
104	Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older. Journal of Clinical Oncology, 2011, 29, 2327-2333.	0.8	177
105	The Influence of Time From Menopause and Mammography on Hormone Therapy-Related Breast Cancer Risk Assessment. Journal of the National Cancer Institute, 2011, 103, 284-285.	3.0	15
106	Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women. JAMA - Journal of the American Medical Association, 2011, 305, 267.	3.8	199
107	Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecologic Oncology, 2010, 116, 323-325.	0.6	55
108	Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial. Journal of the National Cancer Institute, 2010, 102, 1413-1421.	3.0	100

#	Article	IF	Citations
109	Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women. JAMA - Journal of the American Medical Association, 2010, 304, 1684.	3.8	457
110	Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Caseâ€"Control Study. Journal of the National Cancer Institute, 2010, 102, 26-38.	3.0	182
111	Ovarian Cancer Biomarker Screening: Still Too Early to Tell. Women's Health, 2010, 6, 487-490.	0.7	9
112	Lung cancer and hormone replacement therapy â€" Authors' reply. Lancet, The, 2010, 375, 118-119.	6.3	1
113	Lifestyle Factors and Risk of Breast Cancer: A Review of Randomized Trial Findings. , 2010, , 23-41.		0
114	Ambient Fine Particulate Matter Exposure and Myocardial Ischemia in the Environmental Epidemiology of Arrhythmogenesis in the Womenâ€™s Health Initiative (EEAWHI) Study. Environmental Health Perspectives, 2009, 117, 751-756.	2.8	36
115	Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women. New England Journal of Medicine, 2009, 360, 573-587.	13.9	412
116	Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women. Journal of the National Cancer Institute, 2009, 101, 48-60.	3.0	465
117	Multivitamin Use and Risk of Cancer and Cardiovascular Disease in the Women's Health Initiative Cohorts. Archives of Internal Medicine, 2009, 169, 294.	4.3	175
118	Benefits and Risks of Postmenopausal Hormone Therapy When It Is Initiated Soon After Menopause. American Journal of Epidemiology, 2009, 170, 12-23.	1.6	211
119	Heart Rate Variability, Ambient Particulate Matter Air Pollution, and Glucose Homeostasis: The Environmental Epidemiology of Arrhythmogenesis in the Women's Health Initiative. American Journal of Epidemiology, 2009, 169, 693-703.	1.6	63
120	Southwest Oncology Group Trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. Gynecologic Oncology, 2009, 114, 206-209.	0.6	11
121	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics, 2009, 41, 585-590.	9.4	434
122	Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	6.3	282
123	Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. JAMA - Journal of the American Medical Association, 2008, 299, 1036.	3.8	344
124	Insulin, Insulin-like Growth Factor-I, Endogenous Estradiol, and Risk of Colorectal Cancer in Postmenopausal Women. Cancer Research, 2008, 68, 329-337.	0.4	191
125	The Women's Health Initiative: Lessons Learned. Annual Review of Public Health, 2008, 29, 131-150.	7.6	82
126	The Role of Antioxidants and Vitamin A in Ovarian Cancer: Results From the Women's Health Initiative. Nutrition and Cancer, 2008, 60, 710-719.	0.9	36

#	Article	IF	Citations
127	Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal Women. American Journal of Epidemiology, 2008, 167, 1207-1216.	1.6	126
128	Conjugated Equine Estrogens and Breast Cancer Risk in the Women's Health Initiative Clinical Trial and Observational Study. American Journal of Epidemiology, 2008, 167, 1407-1415.	1.6	126
129	Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. Obstetrical and Gynecological Survey, 2008, 63, 440-442.	0.2	1
130	Low-Fat Dietary Pattern and Cancer Incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. Journal of the National Cancer Institute, 2007, 99, 1534-1543.	3.0	194
131	Predicting Risk of Breast Cancer in Postmenopausal Women by Hormone Receptor Status. Journal of the National Cancer Institute, 2007, 99, 1695-1705.	3.0	117
132	Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women. Journal of the National Cancer Institute, 2007, 99, 1782-1792.	3.0	284
133	Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials. Clinical Trials, 2007, 4, 207-217.	0.7	23
134	Long-Term Exposure to Air Pollution and Incidence of Cardiovascular Events in Women. New England Journal of Medicine, 2007, 356, 447-458.	13.9	1,538
135	Effects of Blood Collection Conditions on Ovarian Cancer Serum Markers. PLoS ONE, 2007, 2, e1281.	1.1	42
136	Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer. New England Journal of Medicine, 2006, 354, 684-696.	13.9	907
137	Coronary Heart Disease and Stroke with Aromatase Inhibitor, Tamoxifen, and Menopausal Hormone Therapy Use. Clinical Breast Cancer, 2006, 6, S58-S64.	1.1	26
138	Calcium plus Vitamin D Supplementation and the Risk of Fractures. New England Journal of Medicine, 2006, 354, 669-683.	13.9	1,674
139	Bead-Based ELISA for Validation of Ovarian Cancer Early Detection Markers. Clinical Cancer Research, 2006, 12, 2117-2124.	3.2	136
140	Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas, 2006, 55, 103-115.	1.0	214
141	Combined Analysis of Women's Health Initiative Observational and Clinical Trial Data on Postmenopausal Hormone Treatment and Cardiovascular Disease. American Journal of Epidemiology, 2006, 163, 589-599.	1.6	157
142	Low-Fat Dietary Pattern and Risk of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2006, 295, 655.	3.8	939
143	Low-Fat Diet and Cardiovascular Diseaseâ€"Reply. JAMA - Journal of the American Medical Association, 2006, 296, 279.	3.8	1
144	Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. JAMA - Journal of the American Medical Association, 2006, 295, 1647.	3.8	497

#	Article	IF	Citations
145	Low-Fat Dietary Pattern and Risk of Colorectal Cancer. JAMA - Journal of the American Medical Association, 2006, 295, 643.	3.8	355
146	Low-Fat Dietary Pattern and Risk of Invasive Breast Cancer. JAMA - Journal of the American Medical Association, 2006, 295, 629.	3.8	696
147	Concerns about published data from the estrogen-progestin (HT) arm of the WHI. American Journal of Obstetrics and Gynecology, 2005, 192, 333.	0.7	1
148	Statistical Issues Arising in the Women's Health Initiative. Biometrics, 2005, 61, 899-911.	0.8	60
149	Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome. Journal of the National Cancer Institute, 2005, 97, 439-448.	3.0	539
150	Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy. JAMA - Journal of the American Medical Association, 2004, 291, 1701.	3.8	3,881
151	AIR POLLUTION AND CARDIOVASCULAR DISEASE EVENTS IN THE WOMENâ€™S HEALTH INITIATIVE OBSERVATIONAL (WHI-OS) STUDY. Epidemiology, 2004, 15, S28-S29.	1.2	3
152	The case for early detection. Nature Reviews Cancer, 2003, 3, 243-252.	12.8	1,014
153	Selecting Differentially Expressed Genes from Microarray Experiments. Biometrics, 2003, 59, 133-142.	0.8	177
154	The women's health initiative recruitment methods and results. Annals of Epidemiology, 2003, 13, S18-S77.	0.9	653
155	Implementation of the women's health initiative study design. Annals of Epidemiology, 2003, 13, S5-S17.	0.9	655
156	Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures<SUBTITLE>The Women's Health Initiative Randomized Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2003, 290, 1739.	3.8	466
157	Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA - Journal of the American Medical Association, 2002, 288, 321-333.	3.8	14,536
158	Estimation of the Correlation Between Nutrient Intake Measures Under Restricted Sampling. Biometrics, 1999, 55, 711-717.	0.8	8
159	Individually randomized intervention trials for disease prevention and control. Statistical Methods in Medical Research, 1999, 8, 287-309.	0.7	14
160	Approaches to monitoring the results of long-term disease prevention trials: Examples from the Women's Health Initiative. Contemporary Clinical Trials, 1996, 17, 509-525.	2.0	104
161	Model Misspecification in Proportional Hazards Regression. Biometrika, 1995, 82, 527.	1.3	6
162	A cautionary note on inference for marginal regression models with longitudinal data and general correlated response data. Communications in Statistics Part B: Simulation and Computation, 1994, 23, 939-951.	0.6	288

#	Article	IF	Citations
163	Statistical design and monitoring of the carotene and retinol efficacy trial (CARET). Contemporary Clinical Trials, 1993, 14, 308-324.	2.0	63
164	Effects on response rates and costs of stamps vs business reply in a mail survey of physicians. Journal of Clinical Epidemiology, 1993, 46, 455-459.	2.4	39
165	Two-Stage Experimental Designs: Early Stopping with a Negative Result. Journal of the Royal Statistical Society Series C: Applied Statistics, 1992, 41, 181.	0.5	47
166	Correlates of maintenance of a low-fat diet among women in the Women's Health Trial. Preventive Medicine, 1992, 21, 279-291.	1.6	63